CN100402529C - 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物 - Google Patents

用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物 Download PDF

Info

Publication number
CN100402529C
CN100402529C CNB038249901A CN03824990A CN100402529C CN 100402529 C CN100402529 C CN 100402529C CN B038249901 A CNB038249901 A CN B038249901A CN 03824990 A CN03824990 A CN 03824990A CN 100402529 C CN100402529 C CN 100402529C
Authority
CN
China
Prior art keywords
alkyl
phenyl
methyl
group
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038249901A
Other languages
English (en)
Chinese (zh)
Other versions
CN1694883A (zh
Inventor
K·巴蒂斯塔
G·比南
P·J·康诺利
A·B·赖茨
T·摩甘罗斯
M·斯科特
S·A·米德莱顿
M·奥尔西尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100402529(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1694883A publication Critical patent/CN1694883A/zh
Application granted granted Critical
Publication of CN100402529C publication Critical patent/CN100402529C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB038249901A 2002-09-09 2003-09-05 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物 Expired - Fee Related CN100402529C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40913402P 2002-09-09 2002-09-09
US60/409,134 2002-09-09

Publications (2)

Publication Number Publication Date
CN1694883A CN1694883A (zh) 2005-11-09
CN100402529C true CN100402529C (zh) 2008-07-16

Family

ID=31978719

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038249901A Expired - Fee Related CN100402529C (zh) 2002-09-09 2003-09-05 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物

Country Status (19)

Country Link
US (3) US7081463B2 (enExample)
EP (1) EP1601674B1 (enExample)
JP (1) JP4712384B2 (enExample)
KR (1) KR20050043935A (enExample)
CN (1) CN100402529C (enExample)
AR (1) AR041205A1 (enExample)
AU (1) AU2003268512A1 (enExample)
BR (1) BR0306309A (enExample)
CA (1) CA2498275C (enExample)
CL (1) CL2003001814A1 (enExample)
EA (1) EA009369B1 (enExample)
MX (1) MXPA05002622A (enExample)
NO (1) NO20051743L (enExample)
NZ (1) NZ538307A (enExample)
PL (1) PL377047A1 (enExample)
RS (1) RS20050208A (enExample)
TW (1) TWI296627B (enExample)
WO (1) WO2004022558A2 (enExample)
ZA (1) ZA200502836B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050043935A (ko) * 2002-09-09 2005-05-11 얀센 파마슈티카 엔.브이. Ｏｒｌ-1 수용체 매개 장애의 치료에 유용한 하이드록시 알킬 치환된 1,3,8-트리아자스피로[4.5]데칸-4-온 유도체
NZ544282A (en) * 2003-05-23 2009-07-31 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
BRPI0616618A2 (pt) * 2005-09-28 2011-06-28 Hoffmann La Roche derivados de indol-3-il-carbonil-azaespiro como antagonistas de receptor de vasopressina
TW200819457A (en) 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
KR20090083954A (ko) * 2006-11-28 2009-08-04 얀센 파마슈티카 엔.브이. 3-(3-아미노-2-(ｒ)-하이드록시프로필)-1-(4-플루오로페닐)-8-(8-메틸나프탈렌-1-일메틸)-1,3,8-트리아자-스피로[4.5]데칸-4-온의 염
KR20090087042A (ko) * 2006-11-28 2009-08-14 얀센 파마슈티카 엔.브이. 알콜 남용, 중독 및 의존증 치료방법
CA2683598C (en) * 2007-04-09 2015-11-17 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
UA107943C2 (xx) * 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
WO2014100719A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
KR102043337B1 (ko) 2014-08-28 2019-11-11 아셰뉴론 에스아 글리코시다제 저해제
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP3383390A4 (en) * 2015-12-02 2019-11-20 Astraea Therapeutics, LLC PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
MA43677A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
KR102800480B1 (ko) 2016-02-25 2025-04-25 아셰뉴론 에스아 피페라진 유도체의 산 부가 염
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
HUE067314T2 (hu) 2017-09-22 2024-10-28 Jubilant Epipad LLC Heterociklusos vegyületek mint PAD gátlók
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
SG11202101651RA (en) 2018-08-22 2021-03-30 Asceneuron S A Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
WO2020039029A1 (en) * 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006545A1 (en) * 1998-07-27 2000-02-10 Schering Corporation High affinity ligands for nociceptin receptor orl-1
EP0997464A1 (en) * 1998-10-23 2000-05-03 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
WO2001007050A1 (en) * 1999-07-26 2001-02-01 Schering Corporation Nociceptin receptor orl-1 agonists for use in treating cough

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US677421A (en) * 1900-10-19 1901-07-02 Kate Hatch Mcrae Cake-beater.
US3155699A (en) 1960-03-30 1964-11-03 Mobay Chemical Corp Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3161644A (en) 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3238216A (en) 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
US3839340A (en) * 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro{8 4.5{9 decanes
US3629267A (en) 1968-10-28 1971-12-21 Smith Kline French Lab Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione
US3859340A (en) 1970-09-09 1975-01-07 Squibb & Sons Inc ' -methylfluorene-2-acetic acid
US4020072A (en) 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
JPS54109983A (en) 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
US4329363A (en) 1978-09-08 1982-05-11 Merck & Co., Inc. Substituted mercapto acid amides and their use
US4526896A (en) 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
JPS57212180A (en) 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
WO1988000190A1 (en) 1986-06-25 1988-01-14 Massachusetts Institute Of Technology Optically active derivatives of glycidol
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4135473A1 (de) 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
WO1993012789A1 (en) 1991-12-27 1993-07-08 Beth Israel Hospital Use of spiperone or spiperone derivatives as immunosuppressant agents
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
WO1995007294A1 (en) 1993-09-09 1995-03-16 Scios Nova Inc. Pseudo- and non-peptide bradykinin receptor antagonists
US5739336A (en) 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
EP0891332B1 (en) 1996-03-29 2004-03-17 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US6013652A (en) 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
DE69803653T2 (de) * 1997-12-05 2002-08-29 F. Hoffmann-La Roche Ag, Basel 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
EP0921125B1 (en) * 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
EP1080091A1 (en) 1998-05-18 2001-03-07 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
SI0970957T1 (enExample) 1998-06-12 2001-12-31 Hoffmann La Roche
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
AR021355A1 (es) 1998-11-20 2002-07-17 Smithkline Beecham Spa Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento
JP2000169476A (ja) 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
WO2001036418A1 (en) 1999-11-17 2001-05-25 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
DE19956598A1 (de) 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
JP2005231995A (ja) * 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2001096337A1 (en) 2000-06-14 2001-12-20 Banyu Pharmaceutical Co.,Ltd 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
WO2002083673A1 (en) * 2001-04-10 2002-10-24 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
NZ528978A (en) 2001-04-18 2004-06-25 Euro Celtique S Spiropyrazole compounds
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
ATE396995T1 (de) 2001-07-23 2008-06-15 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
US20040014955A1 (en) 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
JP2005519921A (ja) 2002-01-28 2005-07-07 ファイザー株式会社 Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物
US20060058553A1 (en) 2002-02-07 2006-03-16 Axys Pharmaceuticals, Inc. Novel bicyclic hydroxamates as inhibitors of histone deacetylase
KR20050043935A (ko) * 2002-09-09 2005-05-11 얀센 파마슈티카 엔.브이. Ｏｒｌ-1 수용체 매개 장애의 치료에 유용한 하이드록시 알킬 치환된 1,3,8-트리아자스피로[4.5]데칸-4-온 유도체
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
CA2546147A1 (en) 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
MX2007002033A (es) 2004-08-19 2007-04-26 Vertex Pharma Moduladores de receptores muscarinicos.
WO2006034110A1 (en) 2004-09-17 2006-03-30 Osi Pharmaceuticals, Inc. (arylamidoaryl) cyanoguanidine compounds as inhibitors of c-kit proto-oncogene
JP2008542375A (ja) 2005-06-02 2008-11-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｏｒｌ−１受容体モジュレーターとして有用な新規３−スピロ環式インドリル誘導体
KR20090087042A (ko) 2006-11-28 2009-08-14 얀센 파마슈티카 엔.브이. 알콜 남용, 중독 및 의존증 치료방법
CA2683598C (en) 2007-04-09 2015-11-17 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
US20100076003A1 (en) 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006545A1 (en) * 1998-07-27 2000-02-10 Schering Corporation High affinity ligands for nociceptin receptor orl-1
EP0997464A1 (en) * 1998-10-23 2000-05-03 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
WO2001007050A1 (en) * 1999-07-26 2001-02-01 Schering Corporation Nociceptin receptor orl-1 agonists for use in treating cough

Also Published As

Publication number Publication date
EP1601674A2 (en) 2005-12-07
TWI296627B (en) 2008-05-11
WO2004022558A2 (en) 2004-03-18
WO2004022558A3 (en) 2004-05-21
PL377047A1 (pl) 2006-01-23
JP2006500393A (ja) 2006-01-05
AR041205A1 (es) 2005-05-11
KR20050043935A (ko) 2005-05-11
US20040142955A1 (en) 2004-07-22
ZA200502836B (en) 2006-06-28
CL2003001814A1 (es) 2005-02-11
EP1601674B1 (en) 2012-08-08
US20060030577A1 (en) 2006-02-09
EA009369B1 (ru) 2007-12-28
RS20050208A (sr) 2007-08-03
NZ538307A (en) 2008-04-30
US20090124614A1 (en) 2009-05-14
US7081463B2 (en) 2006-07-25
CA2498275A1 (en) 2004-03-18
BR0306309A (pt) 2004-10-19
CA2498275C (en) 2011-07-12
US7582649B2 (en) 2009-09-01
JP4712384B2 (ja) 2011-06-29
US8778956B2 (en) 2014-07-15
NO20051743L (no) 2005-05-18
TW200418857A (en) 2004-10-01
CN1694883A (zh) 2005-11-09
MXPA05002622A (es) 2005-09-08
EA200500331A1 (ru) 2005-08-25
AU2003268512A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
CN100402529C (zh) 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物
DE60021630T2 (de) Tricyclische kondensierte heterocyclische Verbindungen als CRF Antagonisten
TW202043212A (zh) Shp2抑制劑及其應用
DE69531476T2 (de) Serotonergische Modulatoren
CN109843888A (zh) 可用于治疗癌症的6，7，8，9-四氢-3H-吡唑并[4，3-f]异喹啉衍生物
CN101679430B (zh) 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物
CN106164076B (zh) 作为ros1抑制剂的化合物
CN102939283A (zh) 可用作己酮糖激酶抑制剂的吲唑化合物
TW201111356A (en) Nitrogen-containing compound and pharmaceutical composition
DE60206952T2 (de) Imidazopyridinverbindungen als 5-ht4-rezeptormodulatoren
CA2468705A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
JPS60215683A (ja) 新規縮合ジアゼピノン
DE69829317T2 (de) Tetrahydrobenzindol-derivate
CN101227903A (zh) 用作orl-1受体调节剂的新型3-螺环吲哚基衍生物
CN101321726A (zh) 新型稠合吡咯衍生物
CN119384420A (zh) 新型par-2抑制剂
Modica et al. Design, synthesis and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands
AU594489B2 (en) Substituted pyrido(2,3-b)(1,4) Benzodiazepin-6-ones
CA1321996C (en) Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
HU228314B1 (hu) Kemokin receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HU211156A9 (en) Condensed diazepinones
JP2574348B2 (ja) 新規縮合ジアゼピノン、その製造法及びそれを含有する医薬組成物
DE602004005893T2 (de) Trizyklische 1-((3-indol-3-yl)-carbonyl)-piperazin-derivate als cannabinoid-cb1-rezeptoragonisten
KR20200118008A (ko) 테트라하이드로피롤계 화합물, 그의 제조방법, 약학조성물 및 용도
EP3530651A1 (en) Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080716

Termination date: 20170905

CF01 Termination of patent right due to non-payment of annual fee